Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Japanese patients with advanced cancer
NCT02014129Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2013
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in solid tumor (advanced stage) and lymphoma (3 cohorts), sponsored by Eli Lilly and Company. Primary endpoint: Dose-Limiting Toxicity. Started Dec 2013; status: completed.
02
Drugs
abemaciclib
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT02014129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014129.